| Popis: |
BACKGROUND Cancer patients undergoing cytotoxic chemotherapy face an elevated risk of developing serious infection as a consequence of their treatment, which lowers their white blood cell (WBC) count and, more specifically, their absolute neutrophil count (ANC). This condition is known as neutropenia. Neutropenia accompanied by a fever is referred to as febrile neutropenia (FN), a common side effect of chemotherapy with a high mortality rate. Timely detection of severe neutropenia (ANC OBJECTIVE This study aims to evaluate the usability of PointCheck™, a non-invasive optical technology for screening severe neutropenia, with the goal of identifying potential User Interface (UI), functionality, and design issues from the perspective of untrained users. METHODS We conducted a multi-center study using quantitative and qualitative approaches to evaluate the usability of PointCheck™ across N=154 untrained participants. We used a mixed-method approach to gather usability data through user testing observations, a short-answer qualitative questionnaire, and a standardized quantitative System Usability Scale (SUS) survey to assess user experience and satisfaction. RESULTS We found that N=108 (70.1%) of participants scored above 80.8 on the SUS across all sites, with a mean SUS score of 86.1 across all sites. Furthermore, the SUS results indicated that N=145 (96.0%) of users who completed the SUS survey found they learned how to use PointCheck™ very quickly, and N= 141 (93.0%) felt very confident using the device. CONCLUSIONS We have shown that PointCheck™, a novel technology for non-invasive, home-based neutropenia detection, can be safely and effectively operated by first-time users. In a simulated home environment, these users found it easy to use, with a mean SUS score of 86.1, indicating excellent perception of user experience and placing this device within the top 10th percentile of systems evaluated for usability by the SUS. CLINICALTRIAL ClinicalTrials.gov: H12O: NCT04448314 https://clinicaltrials.gov/ct2/show/NCT04448314 BMC: NCT04448301 https://clinicaltrials.gov/ct2/show/NCT04448301 |
